NASDAQ · Financial Statements

Oramed Pharmaceuticals Inc. (ORMP) Revenue, Earnings & Financial Statements

$3.87 NASDAQ: ORMP Market Cap $168.29M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Oramed Pharmaceuticals Inc. most recently reported annual revenue of $2.0M, net profit of $64.0M. Revenue declined at an average annual rate of 7.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Oramed Pharmaceuticals Inc.: Revenue rose from $1.0M in 2015 to $2.0M in 2025, a change of +100.0% over 9 years; net profit was positive in 2 of 10 reported years; operating margin moved from -1561.6% to -754.4%, a shift of +807.2 percentage points; the most recent year shows net profit of $64.0M.

Income Statement — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Revenue$1.0M$2.0M$2.0M$3.0M$3.0M$3.0M$3.0M$1.0M$0$2.0M
Operating Expenses$11.0M$13.0M$16.0M$17.0M$14.0M$27.0M$43.0M$17.0M$13.0M$17.0M
Operating Profit−$10.0M−$11.0M−$14.0M−$15.0M−$12.0M−$24.0M−$41.0M−$16.0M−$13.0M−$15.0M
Operating Margin-1561.6%-438.6%-552.4%-541.3%-433.8%-896.1%-1502.0%-1176.8%—-754.4%
Other Income$0$0$0$0$0$1.0M$3.0M$21.0M−$3.0M$90.0M
Interest$0$0$0$0$0$0$0$4.0M$1.0M$0
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$10.0M−$10.0M−$13.0M−$14.0M−$12.0M−$23.0M−$38.0M$5.0M−$16.0M$75.0M
Tax rate (%)-13.9%-4.0%6.3%-2.1%0.0%0.0%-0.3%0.0%-20.0%15.0%
Net Profit−$11.0M−$10.0M−$13.0M−$14.0M−$12.0M−$22.0M−$38.0M$6.0M−$19.0M$64.0M
EPS−$0.87−$0.79−$0.86−$0.82−$0.56−$0.78−$0.97$0.14−$0.48$1.50

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$2.0M$0$0$0$0$0$0
Operating Expenses$4.0M$3.0M$3.0M$3.0M$4.0M$7.0M$2.0M$2.0M$6.0M$4.0M$3.0M$4.0M
Operating Profit−$4.0M−$3.0M−$3.0M−$3.0M−$4.0M−$4.0M−$2.0M−$2.0M−$6.0M−$4.0M−$3.0M−$4.0M
Operating Margin—————-225.0%——————
Interest$1.0M$1.0M$0$0$0$3.0M$0$0$0$0$0$0
Profit Before Tax$13.0M$2.0M$11.0M−$19.0M−$10.0M−$7.0M$13.0M$59.0M$10.0M$49.0M$102.0M$28.0M
Tax rate (%)0.0%0.0%15.1%-6.1%-4.3%-8.3%-1.0%18.6%-2.2%22.5%23.1%34.9%
Net Profit$13.0M$2.0M$9.0M−$20.0M−$10.0M−$8.0M$13.0M$48.0M$10.0M$38.0M$78.0M$18.0M
EPS$0.33$0.04$0.22−$0.48−$0.26−$0.19$0.31$1.13$0.23$0.91$1.84$0.43

Over the 10 years reported for Oramed Pharmaceuticals Inc., cash stood at $46.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Total Assets$43.0M$39.0M$47.0M$35.0M$45.0M$128.0M$162.0M$221.0M$155.0M$231.0M
Current Assets$31.0M$20.0M$31.0M$33.0M$41.0M$95.0M$157.0M$163.0M$143.0M$133.0M
Cash$4.0M$4.0M$5.0M$3.0M$19.0M$77.0M$40.0M$9.0M$54.0M$46.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$5.0M
Fixed Assets$0$0$0$0$0$1.0M$2.0M$2.0M$1.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$39.0M$35.0M$42.0M$30.0M$25.0M$24.0M$118.0M$209.0M$98.0M$174.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$17.0M$19.0M$16.0M$15.0M$12.0M$11.0M$10.0M$58.0M$10.0M$31.0M
Current Liabilities$4.0M$5.0M$5.0M$5.0M$5.0M$7.0M$6.0M$53.0M$6.0M$19.0M
Borrowings$0$0$0$0$0$1.0M$1.0M$52.0M$0$1.0M
Other Liabilities$17.0M$19.0M$16.0M$15.0M$12.0M$11.0M$10.0M$6.0M$10.0M$30.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$26.0M$19.0M$31.0M$19.0M$33.0M$116.0M$152.0M$164.0M$146.0M$200.0M

For Oramed Pharmaceuticals Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $11.0M; free cash flow was positive in 1 of 10 years; financing activities used $5.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Operating Cash Flow$5.0M−$6.0M−$15.0M−$13.0M−$12.0M−$21.0M−$29.0M−$10.0M−$8.0M−$9.0M
Investing Cash Flow−$16.0M$4.0M−$7.0M$11.0M$5.0M−$23.0M$30.0M−$73.0M$106.0M$4.0M
Financing Cash Flow$0$0$0$0$0$0$0$0−$2.0M−$5.0M
Net Cash Flow$1.0M$0$1.0M−$2.0M$16.0M$58.0M−$37.0M−$31.0M$45.0M−$8.0M
Free Cash Flow$5.0M−$6.0M−$15.0M−$13.0M−$13.0M−$22.0M−$29.0M−$11.0M−$8.0M−$11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA1.11
FCF Yield-1.84%
Quick Ratio6.07
Interest Coverage—
Return 1Y77.63%
Return 3Y102.76%
Return 5Y-84.97%

Oramed Pharmaceuticals Inc. (ORMP) financials — frequently asked questions

What is Oramed Pharmaceuticals Inc.'s annual revenue?

Oramed Pharmaceuticals Inc. (ORMP) reported annual revenue of $2.0M in its most recent fiscal year.

What is Oramed Pharmaceuticals Inc.'s net profit?

Oramed Pharmaceuticals Inc. (ORMP) reported net profit of $64.0M in its most recent fiscal year.

What is ORMP EV/EBITDA?

Oramed Pharmaceuticals Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 1.11.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
ORMP Overview ORMP Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.